Japan Lifeline (7575) Q2 2025 earnings summary

Executive summary

• Achieved record-high net sales of ¥27,985 million (up 11.4% year-over-year), operating profit of ¥6,260 million (up 14.4%), and net profit of ¥4,435 million (up 10.0%) for H1 FYE March 2025.

• Growth driven by strong performance in EP/Ablation (+16.3%), core product group, and new product launches in neurovascular and gastrointestinal fields.

• H1 results exceeded initial guidance, with net sales at 105.2%, operating profit at 118.1%, and net profit at 116.7% of H1 targets.

• Impact from June 2024 insurance reimbursement price revision offset by higher sales volumes and favorable product mix.

• SG&A expenses rose due to higher personnel costs, IT investments, and one-time provisions for doubtful accounts.

Financial highlights

• Gross profit rose 11.4% year-over-year to ¥16,963 million, with gross margin stable at 60.6%.

• EPS increased 18.0% year-over-year to ¥61.87.

• Q2 (Jul–Sept) net sales grew 14.8% year-over-year to ¥13,974 million, operating profit up 33.5% to ¥3,065 million, and net profit up 23.0% to ¥2,094 million.

• Cash and cash equivalents at period end: ¥8,047 million, down ¥4,621 million from March 2024.

• Sales of third-party products increased 15% year-over-year, notably in neurovascular and hemostatic devices.

Outlook and guidance

• No revision to full-year guidance; H1 results put the company on track to achieve full-year targets.

• Full-year forecast: net sales ¥54,000 million (+5.1%), operating profit ¥11,200 million (+2.8%), net income ¥8,000 million (+6.4%), EPS ¥113.58.

• Sales momentum expected to remain strong across most segments, with some seasonal and market-driven fluctuations anticipated.

• New product launches and expanded product portfolio expected to drive further growth, especially in neurovascular and gastrointestinal areas.